Business & regional news

Comparative data and systematic literature review released at VIVA 2024 show breadth and depth of data supporting atherectomy as a treatment for peripheral arterial disease

The VT research will provide important clinical evidence in an underserved patient population

Global expansion of the Avalus Ultra valve continues in Western Europe while company highlights robust, innovative Cardiac Surgery portfolio at EACTS in Lisbon

Company recognized among top 52 global companies making positive social impact through core business strategy

ADAPT-PD trial methods and preliminary data published in npj Parkinson’s disease

The company will present clinical evidence in young children, pregnancy and type 2 diabetes*

Post-market data collection will add real-world experience to established safety, efficacy, and efficiency evidence profile

New York Valves 2024: Late-breaking data included a SMART Trial secondary analysis showing significantly less bioprosthetic valve dysfunction with Evolut TAV across the entire range of small annulus areas when compared with the Edwards Sapien 3™ TAV platform, and CoreValve-Evolut pooled analysis demonstrating valve performance and durability benefits versus surgery.

Medtronic will present the latest data on its MiniMed™ 780G insulin pump and showcase the company’s latest CareLink™ experience launching globally this month

Medtronic, a global leader in medical technology, announced today that it has received U.S. FDA Breakthrough Device designation for Infuse™ bone graft with an intervertebral fusion device and a...

The company is pursuing hernia and gynecology indications along with urology as it progresses plans to bring choice in robotic surgery technology and partnership to the U.S. Medtronic, a global...

Preliminary findings of the first and only head-to-head trial comparing standard-of-care CT-guided biopsy with electromagnetic navigation bronchoscopy (ENB) for the diagnosis of lung nodules demonstrate non-inferiority and fewer complications when using ENB

Symplicity Spyral is the first renal denervation technology to be approved by the National Medical Products Administration; new, innovative, minimally invasive procedure uses radiofrequency energy to help reduce high blood pressure

Medtronic, the global leader in healthcare technology, today announced the release of important clinical outcomes in two leading transcatheter valve therapies. The results for these studies were...

Study shows the investigational use of the MiniMed™ 780G system improved glycemic control during pregnancy. Medtronic, a global leader in healthcare technology, today announced the results of...

Next-generation Avalus Ultra valve is Medtronic’s most advanced surgical aortic tissue valve built on 10 years of clinical experience with the Avalus™ valve

Medtronic today announced it received a license from Health Canada for its Symplicity Spyral™ multi-electrode Renal Denervation (RDN) System. This is indicated for the management of essential...

CRT 2024: Evolut TAVR is a safe, effective, and economically cost-effective treatment option for low-risk severe aortic stenosis patients compared to surgery up to four years

Medtronic, a global leader in medical technology, announced today the launch of the new UNiD™ ePRO service in the United States. This solution will change the way patient outcomes are collected...

Medtronic will unveil the MiniMed™ 780G system with Simplera Sync™, a new disposable, all-in-one sensor.*

Physician feedback confirms clinical evidence: safe, efficient, and effective treatment offers most versatile new option for atrial fibrillation

86% of subjects preferred closed-loop SCS in a multicenter, randomized, crossover, single blind study of Medtronic’s investigational closed-loop SCS system at one month

24-month European RCT data demonstrates long-term superiority of DTM™ SCS compared with conventional medical management (CMM) for indicated chronic back pain patients not eligible for spine surgery

The next-generation DBS technology is now available in a rechargeable option

Simplicity, efficiency, efficacy with unmatched safety data to set a new standard in catheter ablation

NOVA Study: On-label, prospective, multicenter, randomized controlled trial compared DTM™ SCS to conventional spinal cord stimulation

Next-Gen Evolut FX TAVI system enhances procedure ease-of-use, visualization, and predictability

• Improved survival with ICD therapy: nearly 25% lower risk of death in indicated patients receiving an ICD vs. no ICD
• ICDs confer additional long-term benefits after initial device replacement

40-site pilot program across US, UK, and Europe aims to introduce cutting edge AI solutions into the clinical environment to improve patient care and efficiency

Orders will be processed immediately and shipments will start in the coming weeks

SCAI 2023 Scientific Sessions: Harmony™ Transcatheter Pulmonary Valve System Demonstrates Strong Clinical and Hemodynamic Outcomes at Two Years

Heart Rhythm 2023: Late-breaking analysis of the PULSED AF Trial reveals first of its kind significant, meaningful quality of life improvements and healthcare utilization benefits of the PulseSelect Pulsed Field Ablation System

ACC.23/WCC Late-Breaking Clinical Trial: Evolut™ is only TAVR to show excellent outcomes in low-risk patients at 3 years

CRT 2023 Late-Breaking Data: CoreValve/Evolut™ platform demonstrates significantly lower bioprosthetic valve dysfunction compared to surgery at five years

ADVANCE Trial compares sac regression in the Medtronic Endurant™ II/IIs stent graft system and the Gore® Excluder®* AAA Device Family systems

Late-breaking clinical presentations at VIVA show IN.PACT™ Admiral™ drug-coated PTA balloon catheter outperforms bare metal stents; maintains performance in real-world setting

Study data show clinically meaningful impact on quality of life and disease severity, even in the most complex patients

Medtronic announced today that it recently received CE mark for its Radiant™ balloon-expandable covered stent, the first and currently only covered stent indicated for use in ChEVAR with the...

TCT 2022: Late-breaking data from Intrepid™ Pilot Study 3-year follow-up & 1-year follow-up from Transfemoral EFS study demonstrate promising valve performance Medtronic today announced new data...